Skip to main content

Mark Pegram, MD, Discusses the HER2CLIMB Trial and Promising Nature of Tucatinib Therapy

Dr Pegram spoke about the basis, findings, and clinical significance of the HER2CLIMB trial examining tucatinib therapy for HER2-positive breast cancer.